PHP
Parkman Healthcare Partners Portfolio holdings
AUM
$864M
This Quarter Return
-3.84%
1 Year Return
+33.7%
3 Year Return
+258.24%
5 Year Return
+878.92%
10 Year Return
–
AUM
$546M
AUM Growth
+$546M
(-5.4%)
Cap. Flow
+$43M
Cap. Flow
% of AUM
7.89%
Top 10 Holdings %
Top 10 Hldgs %
37.26%
Holding
117
New
22
Increased
53
Reduced
27
Closed
15
Top Buys
| 1 |
DexCom
DXCM
|
$16.8M |
| 2 |
HCA Healthcare
HCA
|
$13.8M |
| 3 |
Charles River Laboratories
CRL
|
$8.65M |
| 4 |
Cooper Companies
COO
|
$8.01M |
| 5 |
Zimmer Biomet
ZBH
|
$7.97M |
Top Sells
| 1 |
Danaher
DHR
|
$14.6M |
| 2 |
Lantheus
LNTH
|
$13.6M |
| 3 |
Waters Corp
WAT
|
$10.8M |
| 4 |
Neurocrine Biosciences
NBIX
|
$6.29M |
| 5 |
SGEN
Seagen Inc. Common Stock
SGEN
|
$4.35M |
Sector Composition
| 1 | Healthcare | 99.65% |
| 2 | Industrials | 0.35% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
26
Ionis Pharmaceuticals
IONS
$9.64B
| $7.24M | 1.33% |
159,503
+6,451
| +4% | +$293K |
|
|
VRNA
27
Verona Pharma
VRNA
$9.18B
| $6.81M | 1.25% |
417,933
+16,946
| +4% | +$276K |
|
28
Insulet
PODD
$24.2B
| $6.7M | 1.23% |
42,025
-16,026
| -28% | -$2.56M |
|
29
ANI Pharmaceuticals
ANIP
$2.06B
| $6.49M | 1.19% |
111,802
-62,675
| -36% | -$3.64M |
|
30
Akero Therapeutics
AKRO
$3.65B
| $5.87M | 1.08% |
116,107
+81,107
| +232% | +$4.1M |
|
31
Day One Biopharmaceuticals
DAWN
$766M
| $5.72M | 1.05% |
466,408
+38,129
| +9% | +$468K |
|
32
89bio
ETNB
$1.37B
| $5.61M | 1.03% |
363,553
+14,678
| +4% | +$227K |
|
33
Amgen
AMGN
$153B
| $5.38M | 0.98% |
+20,000
| New | +$5.38M |
|
34
Inspire Medical Systems
INSP
$2.53B
| $5.34M | 0.98% |
26,923
+12,453
| +86% | +$2.47M |
|
35
Travere Therapeutics
TVTX
$1.75B
| $5.16M | 0.95% |
577,494
+431,171
| +295% | +$3.85M |
|
36
Veracyte
VCYT
$2.41B
| $5.04M | 0.92% |
225,872
+13,912
| +7% | +$311K |
|
37
Applied Therapeutics
APLT
$73.7M
| $4.36M | 0.8% |
+1,750,000
| New | +$4.36M |
|
38
Sutro Biopharma
STRO
$85.6M
| $4.1M | 0.75% |
1,182,168
+38,307
| +3% | +$133K |
|
39
Cullinan Oncology
CGEM
$456M
| $3.97M | 0.73% |
438,745
+91,964
| +27% | +$832K |
|
40
Supernus Pharmaceuticals
SUPN
$2.52B
| $3.81M | 0.7% |
138,172
-52,007
| -27% | -$1.43M |
|
41
Castle Biosciences
CSTL
$673M
| $3.79M | 0.7% |
224,592
+76,590
| +52% | +$1.29M |
|
|
SILK
42
DELISTED
Silk Road Medical, Inc. Common Stock
SILK
| $3.74M | 0.68% |
249,341
-58,184
| -19% | -$872K |
|
43
Arcus Biosciences
RCUS
$1.24B
| $3.68M | 0.67% |
205,109
+85,060
| +71% | +$1.53M |
|
|
CTLT
44
DELISTED
CATALENT, INC.
CTLT
| $3.67M | 0.67% |
80,646
-60,604
| -43% | -$2.76M |
|
45
IDEAYA Biosciences
IDYA
$2.26B
| $3.58M | 0.66% |
132,701
+5,362
| +4% | +$145K |
|
|
46
Lantheus
LNTH
$3.75B
| $3.47M | 0.64% |
49,889
-195,658
| -80% | -$13.6M |
|
47
CVRx
CVRX
$204M
| $3.37M | 0.62% |
222,120
+81,357
| +58% | +$1.23M |
|
48
SI-BONE Inc
SIBN
$700M
| $3.29M | 0.6% |
155,046
+16,131
| +12% | +$343K |
|
49
Insmed
INSM
$30.3B
| $3.16M | 0.58% |
+125,000
| New | +$3.16M |
|
50
Syndax Pharmaceuticals
SNDX
$1.39B
| $3.08M | 0.57% |
212,448
+4,182
| +2% | +$60.7K |
|